Drug Trial Radar · NCT04725175
Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Feb 26, 2021
Primary completion
Sep 1, 2021
Study completion Sep 1, 2021
Sponsor
- Lead sponsor
- Contineum TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind study of PIPE-307 or placebo in normal healthy subjects. The study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD) study enrolling approximately 48 subjects for a total duration of 6 weeks. Part 2 will be a Multiple Ascending Dose (MAD) study enrolling approximately 24 subjects for a total duration of 7 weeks, and part 3 will be a selected SAD cohort in a fed state to evaluate the effect of food on the bioavailability of PIPE-307, enrolling approximately 8 subjects from a selected SAD cohort for a duration of 6 weeks.
Conditions
- Multiple Sclerosis
Interventions
PIPE-307Drug
Single and multiple ascending oral doses of PIPE-307 tablets
Placebo oral tabletDrug
Single and multiple ascending oral doses of matching Placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Treatment-Emergent Adverse Events (TEAE)Time frame: From baseline to 7 days post dosing for SAD cohorts and 21 days post dosing for MAD cohorts
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Linear Clinical Research
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.